Executive Summary
Pediatrics Benefit-Risk Analysis
Pediatric benefit-risk assessment requires fundamentally different approaches than adult BRA: developing bodies create unique safety concerns, dosing must account for age-dependent pharmacokinetics, efficacy endpoints may differ from adult studies, and regulatory frameworks (PREA, PIP) mandate specific pediatric development obligations. ArcaScience's pediatric BRA methodology is designed for the full spectrum of pediatric drug development from neonates through adolescents.
The platform integrates age-stratified safety analysis, growth and developmental milestone monitoring, pediatric-specific adverse event classification, and extrapolation modeling from adult efficacy data. Pediatric models address the statistical challenges of small pediatric populations, age-appropriate formulation safety assessment, and long-term safety monitoring for medications administered during critical developmental windows.
Key Takeaways
4 Pediatrics-Specific Innovations
Age-Stratified Analysis
Automated age-stratified safety assessment across neonatal, infant, child, and adolescent categories with age-appropriate reference ranges and developmental milestone integration.
Growth Monitoring
Specialized growth trajectory analysis integrating height, weight, BMI, bone age, and sexual maturation markers (Tanner staging) for medications affecting growth.
Extrapolation Framework
Evidence-based extrapolation modeling from adult to pediatric populations, assessing disease similarity, PK/PD bridging, and exposure-response relationship transferability.
Developmental Safety
Long-term neurodevelopmental and behavioral safety monitoring covering cognitive development, academic performance, and psychiatric outcomes for chronic pediatric therapies.
Whitepaper Contents
8 Comprehensive Chapters
Download
Get the Full Pediatrics BRA Methodology Guide
Complete the form below to receive the document via email.
Related Resources